NERVGEN PHARMA CORP.
corporate_fare Company Profile
NERVGEN PHARMA CORP. (NASDAQ:NGEN) is a publicly traded company in the Life Sciences sector. Wiseek monitors NGEN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- NervGen Pharma Establishes $50M At-The-Market Equity Program
- NervGen Reports Strong Phase 1b/2a Gait Analysis Data for NVG-291, Showing Neural Recovery
- NervGen Pharma Increases Shelf Offering Capacity to $250 Million Amidst Going Concern Warning
- NervGen's NVG-291 Demonstrates Genuine Neural Recovery in Spinal Cord Injury Study
- NervGen Pharma Prices $60M Public Offering at Premium to Market, Securing Critical Funding
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for NGEN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
New ATM Program Established · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.